Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

American mayapple contains anticancer compounds: Study

A common weed called American mayapple may soon offer an alternative to an Asian cousin that's been harvested almost to extinction because of its anti-cancer properties.

5 Sep 2009

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable prior year quarter. This increase was primarily generated from increased government contract revenue and from increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

3 Sep 2009

Alternative device for increased specificity of bronchoscopic lung cancer detection

Research published in the September 2009 issue of the Journal of Thoracic Oncology has found that narrow-band imaging bronchoscopy increases the specificity of bronchoscopic early lung cancer detection and can serve as an alternative detection device.

3 Sep 2009

Avastin increases survival rates in recurrent glioblastoma affected patients

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.

3 Sep 2009

Patients with advanced NSCLC predict their overall survival rates

Research published in the September 2009 issue of the Journal of Thoracic Oncology has found that an individual's quality of life prior to treatment can help predict the overall survival of patients with advanced stage non-small cell lung cancer (NSCLC).

3 Sep 2009

Cyberknife Robotic Radiosurgery System to be showcased at the ESTRO conference

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that the company will showcase the treatment planning capabilities of the CyberKnife(R) Robotic Radiosurgery System at the 10th Biennial European Society for Therapeutic Radiology and Oncology (ESTRO) Conference on Physics and Radiation Technology for Clinical Radiotherapy in Maastricht, The Netherlands.

31 Aug 2009

Abbott to partner with Pfizer to develop a companion diagnostic test for non-small cell lung cancer

Abbott announced today that it has entered into an agreement with Pfizer Inc to develop a molecular diagnostic test intended to screen non-small cell lung cancer (NSCLC) tumors for the presence of gene rearrangements.

28 Aug 2009

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.

27 Aug 2009

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

Endocyte, Inc., a cancer drug discovery and development company, today announced it has received a milestone payment from Bristol-Myers Squibb Company (NYSE: BMY). This payment was triggered by the commencement of a Phase II clinical trial for an epothilone-folate anti-cancer agent identified through the collaboration between Endocyte and Bristol-Myers Squibb scientists.

26 Aug 2009

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

The genes that may contribute to drug resistance in non-small cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.

26 Aug 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

More evidence that genes increase a smokers' risk of lung cancer

Cancer Research UK funded scientists have confirmed that inherited changes in certain regions of the genome can increase a smokers' risk of developing lung cancer lung cancer, and determine the type of lung cancer that develops. Their results were published in this week's edition of the journal Cancer Research*.

21 Aug 2009

Poniard Pharmaceuticals may sell up to $60 million of its registered common stock to finance its picoplatin clinical development and commercialization programs

...

20 Aug 2009

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it will participate in the Southern California Investor Conference being held in Newport Beach, CA, on Tuesday August 18, 2009.

19 Aug 2009

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech, Inc. today announced that a Phase III study (RIBBON 2) of Avastin (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.

18 Aug 2009

U.S. District Court rules against Lilly regarding Gemzar patent

Eli Lilly and Company today announced that the U.S. District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment.

17 Aug 2009

Oncothyreon reports Q2 2009 financials

Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008.

12 Aug 2009

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.

12 Aug 2009

Cephalon, Inc. completes acquisition of Arana Therapeutics

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of all of the outstanding ordinary shares of Australian biotechnology company, Arana Therapeutics Limited. As a result of the acquisition, Arana is now a wholly-owned subsidiary of Cephalon.

10 Aug 2009

Small Cell Lung Cancer News and Research

American mayapple contains anticancer compounds: Study

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Alternative device for increased specificity of bronchoscopic lung cancer detection

Avastin increases survival rates in recurrent glioblastoma affected patients

Patients with advanced NSCLC predict their overall survival rates

Cyberknife Robotic Radiosurgery System to be showcased at the ESTRO conference

Abbott to partner with Pfizer to develop a companion diagnostic test for non-small cell lung cancer

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

More evidence that genes increase a smokers' risk of lung cancer

Poniard Pharmaceuticals may sell up to $60 million of its registered common stock to finance its picoplatin clinical development and commercialization programs

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

U.S. District Court rules against Lilly regarding Gemzar patent

Oncothyreon reports Q2 2009 financials

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Cephalon, Inc. completes acquisition of Arana Therapeutics

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News